Lisinopril and Tadalafil Interaction: Safety, Risks, and Clinical Guidance

Lisinopril is an ACE inhibitor (brand names Prinivil, Zestril) used for hypertension, heart failure, and after certain heart attacks. Tadalafil is a PDE5 inhibitor sold as Cialis for erectile dysfunction and as a once-daily low-dose product for benign prostatic hyperplasia symptoms; it is also marketed as Adcirca for pulmonary arterial hypertension at different dosing. This article is about tadalafil used for ED or BPH alongside lisinopril, not the pulmonary hypertension indication.

The direct answer

Combining an ACE inhibitor like lisinopril with a PDE5 inhibitor like tadalafil is a recognized, additive blood-pressure-lowering interaction rather than a dangerous one. Current FDA prescribing information for PDE5 inhibitors describes them as mild systemic vasodilators and notes that co-administration with antihypertensive medications, including ACE inhibitors, can produce a further modest drop in blood pressure on top of existing therapy. This is fundamentally different from the nitrate-PDE5 inhibitor combination, which is contraindicated because both act on the same nitric oxide/cGMP pathway and can cause a severe, treatment-resistant blood pressure crash. Anyone starting tadalafil while on lisinopril should still confirm the current interaction language with their prescriber or pharmacist, since exact FDA label wording and dosing recommendations should be checked in the label current as of the date of use rather than assumed from a secondary summary.

How the two drugs lower blood pressure differently

Lisinopril and tadalafil work through separate signaling systems, which is the pharmacologic reason their effects add up instead of one drug blocking or potentiating the other's metabolism.

Lisinopril (renin-angiotensin-aldosterone pathway). Lisinopril blocks angiotensin-converting enzyme, which prevents the conversion of angiotensin I to angiotensin II. Angiotensin II is a vasoconstrictor and stimulates aldosterone release, so blocking its formation reduces peripheral vascular resistance and sodium retention. Lisinopril is not meaningfully metabolized by the liver; it is cleared largely unchanged by the kidneys, which is one reason it does not compete with drugs cleared through the CYP450 system.

Tadalafil (nitric oxide/cGMP pathway). Tadalafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in vascular smooth muscle. Blocking PDE5 lets cGMP accumulate, which produces vasodilation, most prominently in penile tissue but also, to a lesser degree, systemically. Tadalafil is metabolized mainly by CYP3A4. Lisinopril does not inhibit or induce CYP3A4, so there is no known pharmacokinetic interaction, meaning neither drug changes how much of the other reaches the bloodstream or how quickly it is cleared. Tadalafil's half-life is notably longer than sildenafil's or vardenafil's, which is why its vasodilatory effect persists longer after a single dose, though the exact hours-long figure varies by source and should be confirmed against the current label rather than treated as a fixed number here.

Because the two drugs act on separate systems, the interaction is described as additive (pharmacodynamic) rather than synergistic or metabolic. That distinction matters clinically: an additive effect is generally predictable and manageable with monitoring, while the nitrate interaction is a true synergistic pathway overlap that can be severe.

What is established, what is plausible, and what is not established

Established:

• Lisinopril and tadalafil are not pharmacokinetically interacting drugs; there is no known CYP450 competition between them.
• PDE5 inhibitors as a class, including tadalafil, are described in FDA labeling as mild vasodilators capable of adding to the blood-pressure-lowering effect of antihypertensive drugs, including ACE inhibitors.
• Nitrates remain absolutely contraindicated with tadalafil because of the shared nitric oxide/cGMP mechanism. This is a distinct and far more dangerous interaction than the ACE inhibitor combination.

Plausible but requiring individualized verification:

• The specific magnitude of additional blood pressure drop when tadalafil is added to lisinopril (older summaries cite figures in the range of a few mmHg systolic, but the exact number depends on dose, study population, and baseline blood pressure, and should be confirmed against current tadalafil labeling rather than quoted as a fixed figure).
• Whether daily low-dose tadalafil produces a meaningfully lower rate of symptomatic hypotension than as-needed higher-dose tadalafil when combined with an ACE inhibitor. The pharmacologic rationale (flatter plasma levels, no sharp peak) is reasonable, but a precise comparative event rate was not verifiable from the sources reviewed for this draft and should not be cited as an exact percentage without checking the primary trial data.

Not established from the material reviewed here:

• Any claim that a specific numeric rate of dizziness, syncope, or hypotension applies to lisinopril specifically (as opposed to ACE inhibitors or antihypertensives generally) when combined with tadalafil. The trial data referenced in older versions of this topic describe antihypertensive classes in aggregate, not lisinopril in isolation, and the underlying study identifiers could not be confirmed for this draft.
• Any claim that one ACE inhibitor is safer than another when combined with tadalafil. This is presented as a class effect based on shared mechanism, not because a head-to-head comparison was located.

Who faces higher risk from the combination

The additive blood pressure effect is generally mild in healthy, well-controlled patients, but several factors increase the chance of symptomatic hypotension:

• Older adults. Reduced baroreceptor sensitivity with age blunts the compensatory heart rate increase that normally offsets a blood pressure drop, so orthostatic symptoms are more likely.
• Multiple antihypertensives or diuretics. A patient on lisinopril plus a diuretic or calcium channel blocker already has more vasodilatory or volume-depleting exposure before tadalafil is added.
• Volume depletion. Dehydration, heat exposure, illness with vomiting or diarrhea, or alcohol use around the time of dosing can compound the blood pressure effect.
• Autonomic dysfunction. Conditions such as diabetic neuropathy or Parkinson's disease impair the body's ability to compensate for acute vasodilation and warrant extra caution and closer monitoring.
• Triple combination with an alpha-blocker. Some patients take an alpha-blocker (for example tamsulosin) for prostate symptoms in addition to lisinopril and tadalafil. Three vasodilatory mechanisms together raise hypotension risk further, and prescribers typically confirm the patient is stable on the alpha-blocker before starting a PDE5 inhibitor.

The nitrate distinction, and why it is not the same interaction

Nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) directly donate nitric oxide, which directly raises cGMP. PDE5 inhibitors prevent cGMP from being broken down. Given together, the two effects compound on the same pathway and can cause a severe, sometimes life-threatening drop in blood pressure. This is why nitrates are absolutely contraindicated with any PDE5 inhibitor, a warning that appears prominently in FDA labeling for tadalafil.

Lisinopril does not touch the nitric oxide/cGMP pathway at all. Its blood-pressure effect comes from the renin-angiotensin system, a separate mechanism. The combination with tadalafil is additive rather than pathway-synergistic, which is the pharmacologic reason it is not contraindicated. Patients and clinicians should not extrapolate the nitrate warning onto ACE inhibitors; they are mechanistically different situations with different levels of risk.

Practical points for monitoring, not a dosing instruction

This section describes what clinicians and pharmacists generally consider, not an individualized dosing plan. Any specific dose, timing, or adjustment decision should come from the prescriber managing the patient's full medication list and blood pressure history.

• A baseline blood pressure check, including sitting and standing readings, before the first dose of tadalafil is a reasonable practice, particularly if the patient already has borderline low blood pressure or is on multiple antihypertensives.
• Patients are generally advised to rise slowly from sitting or lying positions after taking tadalafil, since orthostatic symptoms (lightheadedness, visual dimming) are the most common early warning sign of an excessive blood pressure drop.
• Alcohol is a vasodilator and can compound the effect of both drugs; label guidance for tadalafil addresses this directly and is worth reviewing with a pharmacist.
• Heat exposure (saunas, hot tubs, hot weather) and inadequate fluid intake independently lower blood pressure and can stack with the drug effect.
• Emergency evaluation is appropriate for syncope, chest pain, a sustained fast heart rate, or a systolic blood pressure that drops below roughly 90 mmHg with symptoms. These events are uncommon with this specific combination but should never be self-managed.

Evidence-status checklist for this interaction

Common questions

Evidence sources for editorial review

• FDA prescribing information for tadalafil (Cialis) and for ACE inhibitors, searchable through the FDA's Drugs@FDA database: https://www.accessdata.fda.gov/scripts/cder/daf/
• Guideline-level context on erectile dysfunction and cardiovascular risk stratification comes from consensus statements (for example, the Princeton Consensus framework) that categorize patients on multiple antihypertensives as needing closer evaluation before starting a PDE5 inhibitor. The specific article identifiers cited in earlier drafts of this page could not be verified against the correct source and have been removed rather than carried forward incorrectly.
• Claims about specific trial-derived percentages (rates of dizziness, hypotension, or syncope) that appeared in prior versions of this article have been removed or qualified because the underlying citations could not be confirmed as matching the claim. A clinical reviewer with database access should re-verify any numeric claim before it is restored to the page.

This lisinopril information is meant for educational purposes and should not be used instead of personalized guidance from the healthcare provider or pharmacist overseeing a patient's drug therapy.